Share the Video:

Pioneers of MDMA Therapy: Reflections on 20+ Years of MDMA Therapy and Research

PS2023MDMAMDMA-assisted therapyPsychedelic Assisted TherapyPTSDResearch

Keren Tzarfaty, Michael Mithoefer, Julie Holland

In 2004, after nearly two decades of preliminary studies, advocacy, and fundraising, MAPS received approval to begin their clinical trials for MDMA-AT for the treatment of PTSD. Nearly twenty years this first study, in November of 2022, MAPS PBC completed the collection of data for the final study required to file a New Drug Application. This panel presents the stories of the researchers and therapists who made history during this period, yielding the first completed Phase 3 study for a psychedelic drug in history. ACCESS LIMITATION: This session is open to qualified healthcare professionals only. DISCLAIMER: The safety and efficacy of MDMA-assisted therapy is currently under investigation. It has not yet been approved by the FDA or other regulatory authorities, does not work for everyone, and carries risks even in therapeutic settings.

Become a MAPS Member with a monthly donation

As a Member, you’re not just making a donation — you’re joining a community that is at the forefront of advancing research, changing policy, and evolving education around psychedelics. Join us in shaping a future where these life-changing tools are available to those who need them most.

Related Videos

PS2023MDMAMDMA-assisted therapyPolicy and AdvocacyPsychedelic SciencePTSDResearch

The Light of Psychedelics in a Dark World

Rick Doblin reflects on 38 years of MAPS, discussing psychedelic milestones and obstacles. Lykos Therapeutics submits NDA for MDMA-assisted therapy for PTSD in December 2023.

Rick Doblin

PS2023KetamineMDMAPsilocybinPsychedelic Assisted TherapyPsychedelic ScienceResearch

Psychedelics as The Great Disrupters: Reconstructing the Future of Mental Healthcare

Dr. Ben Sessa will discuss similarities among MDMA, ketamine, and psilocybin in clinical settings, exploring their potential in treating trauma-based disorders and challenges in psychedelic medicalization.

Ben Sessa

PS2023MDMAPsychedelic Assisted TherapyResearch

Unlocking the Healing Potential: A Conversation on Experiential Training in MDMA-Assisted Therapy with Payton Nyquvest and Rick Doblin

Payton Nyquvest and Rick Doblin discuss MDMA-Assisted Therapy's transformative potential for healing and mental health in an insightful panel discussion.

PS2023MDMAPsychedelic Assisted TherapyPsychedelic ScienceResearch

Grounding Psychedelic Research in Memory for Advancing Psychedelic Drug Discovery

M.K.D. discusses how psychedelics impact memory formation, suggesting potential for harnessing plasticity. J.K. concludes on how understanding mnemonic effects can shape clinical use and drug design.

James Keim

PS2023KetamineMDMAPsilocybinPsychedelic Assisted TherapyResearchResources for Therapists

Being a Psychedelic Therapist

Speaker discusses underlying assumptions of psychedelic therapy and therapist's role, emphasizing presence in facilitating healing. Draws from personal experiences with MDMA, psilocybin, and ketamine research volunteers.

Norma Stevens

PS2023MDMAPsychedelic Assisted TherapyResearch

Investigational MDMA-assisted therapy and eating disorder symptoms in a randomized placebo-controlled trial for severe PTSD

MDMA-assisted therapy (MDMA-AT) shows promise in treating PTSD and comorbid eating disorders. A study found significant reductions in eating disorder symptoms with MDMA-AT compared to placebo in severe PTSD patients.

Adele LaFrance, Timothy Brewerton

PS2023Health ConditionsMDMAPsychedelic Assisted TherapyPsychedelic ScienceResearchTherapy Ethics

Beyond Ecstasy: Progress in Developing and Understanding a Novel Class of Therapeutic Medicine

MDMA's therapeutic mechanism differs from classical psychedelics, showing potential for treating CNS disorders. Shulgin's 1970s research inspired exploration of modifying MDMA's structure and developing novel compounds for improved effects.

Matthew Baggott

PS2023MDMAPolicy and AdvocacyPsychedelic Assisted TherapyPsychedelic SciencePublic BenefitResearch

Preview Scene from Prescription X: The Rick Doblin and MAPS Documentary (Work in Progress)

"Prescription X: The Rick Doblin Story" documents Dr. Rick Doblin's quest with MAPS to legalize MDMA and psychedelics for therapy, culminating in a revealing film by Nirvan and Dream Mullick.

Nirvan Mullick, Dream Mullick

PS2023Healing for AllIntegrationPsychedelic Assisted TherapyPsychedelic SciencePTSDResearch

Mind-Body Skills Groups as a Potential Ideal Setting for Psychedelic Exploration

James S. Gordon, MD, psychiatrist and author, shares how Mind-Body Skills Groups have reduced PTSD diagnoses by 80%, discussing their techniques and the potential integration of psychedelic experiences.

James Gordon